Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPB2 | Q96IY4 | 10/20 | 0.47 |
| ▸ | NPY4R | P50391 | 6/20 | 0.40 |
| ▸ | NPY1R | P25929 | 4/20 | 0.40 |
| ▸ | NPY2R | P49146 | 2/20 | 0.40 |
| ▸ | NPY5R | Q15761 | 2/20 | 0.40 |
| ▸ | REN | P00797 | 1/20 | 0.40 |
| ▸ | METAP2 | P50579 | 1/20 | 0.40 |
| ▸ | NMT2 | O60551 | 1/20 | 0.39 |
| ▸ | NMT1 | P30419 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30685283 | 0.86 | NPY4R (0.45) | NPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL31253369 | 0.85 | CPB2 (0.46) | CPB2NPY4R | |
| SCHEMBL30676983 | 0.84 | CPB2 (0.50) | CPB2NPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL9819648 | 0.84 | NPY4R (0.41) | NPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL9819642 | 0.84 | NPY4R (0.41) | NPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL29697049 | 0.84 | NPY4R (0.41) | NPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL30799775 | 0.84 | CPB2 (0.48) | CPB2 | |
| SCHEMBL30417895 | 0.83 | CPB2 (0.48) | CPB2 | |
| SCHEMBL30123274 | 0.82 | GNPAT (0.43) | NPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL31265325 | 0.82 | NPY4R (0.43) | NPY4RNPY1RNPY2RNPY5R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12496350-B2 | Cyclic peptidyl inhibitors of CAL-PDZ binding domain | OHIO STATE INNOVATION FOUNDATION (US) | 2025-12-16 | — | — | US | disclosed |
| US-20240173423-A1 | CYCLIC PEPTIDYL INHIBITORS OF CAL-PDZ BINDING DOMAIN | OHIO STATE INNOVATION FOUNDATION | 2024-05-30 | — | — | US | disclosed |
| US-11793884-B2 | Cyclic peptidyl inhibitors of CAL-PDZ binding domain | OHIO STATE INNOVATION FOUNDATION (US) | 2023-10-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11793884-B2 | Cyclic peptidyl inhibitors of CAL-PDZ binding domain | CNBP, CALU, CLSPN | CPB2 129/4885NPY4R 830/4885NPY1R 523/4885 |
| US-20240173423-A1 | CYCLIC PEPTIDYL INHIBITORS OF CAL-PDZ BINDING DOMAIN | CNBP, CALU, CLSPN | CPB2 129/4885NPY4R 830/4885NPY1R 523/4885 |
| US-12496350-B2 | Cyclic peptidyl inhibitors of CAL-PDZ binding domain | CNBP, CALU, CLSPN | CPB2 129/4885NPY4R 830/4885NPY1R 523/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.